Study of APVO436 for untreated AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have AML that has not been treated before.
- Your leukemia cells have a marker called CD123.
- You cannot have standard strong chemotherapy because of age (75+), poor performance status, heart/lung/kidney/liver issues, or other medical reasons.
- You are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a new drug called AK117 combined with two standard AML medicines (azacitidine and venetoclax) for people with acute myeloid leukemia who haven't had certain prior treatments. The goal is to see if this combination works better and is safe.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of three drugs (tretinoin, azacitidine, and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who have not yet received chemotherapy. The goal is to see if this combination can help control the leukemia.
This trial tests a new combination therapy called VAG for people with acute myeloid leukemia (AML) who haven't been treated before. The goal is to see if it works better than standard treatments.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.